iCamuno’s expert team leverages key research findings, as outlined in three published articles in Nature and one in Nature Methods, to form the theoretical foundation that fuels technological innovation with an in-depth understanding of cell fate regulation. By addressing epigenetic abnormalities in iPSC reprogramming, we have derived enhanced pluripotent stem cells, known as iCam-iPSCs. These cells are closer in nature to embryonic stem cells (ESCs), offering heightened safety and pluripotency.

iCamuno’s gene editing platform employs innovative technology to enhance the precision, reliability, and efficiency of gene editing processes. We harness these advancements to optimize the targeting, endurance, and safety of immunotherapy cells, amplifying their effectiveness in combating tumors.

By integrating bioinformatic algorithms with single-cell multi-omics, we formulate innovative protocols that significantly enhance the efficiency and functionality of iPSC expansion and differentiation. This optimization results in more effective effector cells for applications in tumor immunotherapy—including natural killer cells, T-cells, and macrophages—and regenerative medicine—spanning mesenchymal stem cells, cardiomyocytes, dopaminergic neurons, and pancreatic islets.